Lynx Capital Group’s Novo Nordisk NVO Stock Holding History

Lynx Capital Group’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-42,096	Closed	-$2.14M	–	87
2025 Q4	$2.14M	Sell	42,096 -513	-1%	-$26.2K	0.98%	45
2025 Q3	$2.36M	Buy	42,609 +539	+1%	+$31.6K	1.1%	44
2025 Q2	$2.9M	Buy	42,070 +30,788	+273%	+$2.09M	1.4%	34
2025 Q1	$783K	Sell	11,282 -54	-0.5%	-$4.46K	0.4%	55
2024 Q4	$975K	Sell	11,336 -139	-1%	-$15K	0.56%	52
2024 Q3	$1.37M	Sell	11,475 -1,705	-13%	-$227K	0.89%	45
2024 Q2	$1.88M	Sell	13,180 -72	-0.5%	-$9.54K	1.3%	38
2024 Q1	$1.7M	Sell	13,252 -1,760	-12%	-$210K	1.15%	40
2023 Q4	$1.55M	Buy	+15,012	New	+$1.48M	1.13%	41

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Lynx Capital Group's NVO Position: Q1 2026 in Review

Lynx Capital Group sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 42,096 shares — an estimated $2.14M sold.

Lynx Capital Group first reported a position in NVO in Q4 2023 and held it in 9 quarters. The position peaked at $2.9M in Q2 2025. 1,277 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

Lynx Capital Group reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
Lynx Capital Group sold 42,096 Novo Nordisk shares in Q1 2026, an estimated $2.14M.
Lynx Capital Group first reported a position in Novo Nordisk in Q4 2023 and held it in 9 quarters.
Lynx Capital Group's Novo Nordisk position peaked at $2.9M in Q2 2025.
1,277 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Lynx Capital Group's 13F filing for Q1 2026, filed 12 Aug 2026.